作者
Mahmoud R. Fassad,Mitali Patel,Amelia Shoemark,Thomas Cullup,Jane Hayward,Mellisa Dixon,Andrew V. Rogers,Sarah Ollosson,Claire L. Jackson,Patricia Goggin,Robert A. Hirst,Andrew Rutman,James Thompson,Lucy Jenkins,Paul Aurora,Eduardo Moya,Philip Chetcuti,Chris O’Callaghan,Deborah J. Morris‐Rosendahl,Christopher M. Watson,Robert K. Semple,S.B. Carr,Woolf T. Walker,Andreia Pinto,Susana S. Lopes,Heba Morsy,Walaa Shoman,L. Pereira,Carolina Constant,Michael R. Loebinger,Eddie M.K. Chung,Priti Kenia,Nisreen Rumman,Nader Fasseeh,Jane S. Lucas,Claire Hogg,Hannah M. Mitchison
摘要
Background Primary ciliary dyskinesia (PCD), a genetically heterogeneous condition enriched in some consanguineous populations, results from recessive mutations affecting cilia biogenesis and motility. Currently, diagnosis requires multiple expert tests. Methods The diagnostic utility of multigene panel next-generation sequencing (NGS) was evaluated in 161 unrelated families from multiple population ancestries. Results Most (82%) families had affected individuals with biallelic or hemizygous (75%) or single (7%) pathogenic causal alleles in known PCD genes. Loss-of-function alleles dominate (73% frameshift, stop-gain, splice site), most (58%) being homozygous, even in non-consanguineous families. Although 57% (88) of the total 155 diagnostic disease variants were novel, recurrent mutations and mutated genes were detected. These differed markedly between white European (52% of families carry DNAH5 or DNAH11 mutations), Arab (42% of families carry CCDC39 or CCDC40 mutations) and South Asian (single LRRC6 or CCDC103 mutations carried in 36% of families) patients, revealing a striking genetic stratification according to population of origin in PCD. Genetics facilitated successful diagnosis of 81% of families with normal or inconclusive ultrastructure and 67% missing prior ultrastructure results. Conclusions This study shows the added value of high-throughput targeted NGS in expediting PCD diagnosis. Therefore, there is potential significant patient benefit in wider and/or earlier implementation of genetic screening.